Editorial
Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest
Cáncer de próstata resistente a castración no diseminado (CPRCM0), un viejo escenario con interés clínico renovado
a Servicio de Urología, Hospital Vall d’Hebrón, Barcelona, Spain
b Servicio de Oncología Radioterápica, Hospital Vall d’Hebrón, Barcelona, Spain
c Servicio de Oncología Médica, Hospital Vall d’Hebron, Barcelona, Spain
d Programa de Investigación Traslacional en Cáncer de Próstata, Institut de Recerca Vall d’Hebrón, Barcelona, Spain
e Departamento de Fisiología, Universidad Autónoma de Barcelona, Barcelona, Spain
f Universitat Internacional de Catalunya, Spain
Read
311
Timeswas read the article
72
Total PDF
239
Total HTML
Share statistics
array:22 [ "pii" => "S217357861400122X" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2014.06.005" "estado" => "S300" "fechaPublicacion" => "2014-09-01" "aid" => "642" "copyright" => "AEU" "copyrightAnyo" => "2014" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2014;38:419-20" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 320 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 238 "PDF" => 72 ] ] "itemSiguiente" => array:19 [ "pii" => "S2173578614001048" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2014.06.002" "estado" => "S300" "fechaPublicacion" => "2014-09-01" "aid" => "623" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2014;38:421-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 437 "formatos" => array:3 [ "EPUB" => 11 "HTML" => 285 "PDF" => 141 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Preservation of the internal vesical sphincter and proximal urethra during retropubic radical prostatectomy may improve earlier recovery of continence in selected patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "421" "paginaFinal" => "428" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La preservación del esfínter interno vesical y la uretra proximal durante la prostatectomía radical retropúbica puede mejorar la recuperación temprana de la continencia en pacientes seleccionados" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 802 "Ancho" => 1000 "Tamanyo" => 163429 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Standardization of the ring-shaped bladder sphincter and longitudinal smooth muscle of the proximal urethra during dissection of dorsal aspect of the prostate and the neck of the bladder.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Brunocilla, R. Schiavina, M. Borghesi, C. Pultrone, V. Vagnoni, M.S. Rossi, M. Cevenini, L. Bianchi, E. Molinaroli, G. Gentile, G. Martorana" "autores" => array:11 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Brunocilla" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Schiavina" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Borghesi" ] 3 => array:2 [ "nombre" => "C." "apellidos" => "Pultrone" ] 4 => array:2 [ "nombre" => "V." "apellidos" => "Vagnoni" ] 5 => array:2 [ "nombre" => "M.S." "apellidos" => "Rossi" ] 6 => array:2 [ "nombre" => "M." "apellidos" => "Cevenini" ] 7 => array:2 [ "nombre" => "L." "apellidos" => "Bianchi" ] 8 => array:2 [ "nombre" => "E." "apellidos" => "Molinaroli" ] 9 => array:2 [ "nombre" => "G." "apellidos" => "Gentile" ] 10 => array:2 [ "nombre" => "G." "apellidos" => "Martorana" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480614000357" "doi" => "10.1016/j.acuro.2013.12.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480614000357?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578614001048?idApp=UINPBA00004N" "url" => "/21735786/0000003800000007/v1_201408240422/S2173578614001048/v1_201408240422/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "419" "paginaFinal" => "420" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Morote, J. Planas, X. Maldonado, J. Carles" "autores" => array:4 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Morote" "email" => array:1 [ 0 => "jmorote@vhebron.net" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Planas" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 2 => array:3 [ "nombre" => "X." "apellidos" => "Maldonado" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 3 => array:3 [ "nombre" => "J." "apellidos" => "Carles" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Servicio de Urología, Hospital Vall d’Hebrón, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Oncología Radioterápica, Hospital Vall d’Hebrón, Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Oncología Médica, Hospital Vall d’Hebron, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Programa de Investigación Traslacional en Cáncer de Próstata, Institut de Recerca Vall d’Hebrón, Barcelona, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Departamento de Fisiología, Universidad Autónoma de Barcelona, Barcelona, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Universitat Internacional de Catalunya, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cáncer de próstata resistente a castración no diseminado (CPRCM0), un viejo escenario con interés clínico renovado" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The questionable use of androgen suppression in patients with non-metastatic prostate cancer means that often we attend the diagnosis of resistance to castration before the cancer is metastatic (CRPCM0), without having to date a valid therapeutic alternative in this scenario. Most of these patients come from different population groups. Probably the largest is for those who develop biochemical failure after radical prostatectomy and who have received adjuvant or salvage radiotherapy. Another group of patients is made up of patients who have not received radiotherapy because they had a biochemical relapse with high-risk criteria for dissemination, and, finally, the group of patients who were treated with radical purpose by means of radiotherapy and neoadjuvant hormone therapy for periods ranging between 6 months and 3 years. The whole sum of these patients currently represents over 80% of those who reach the castration-resistant status.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The current scenario incorporates type I evidence, which proves the effectiveness of new forms of hormone therapy in patients with CRPC and disseminated disease, asymptomatic or mildly symptomatic.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> These new therapeutic modalities come to occupy a treatment niche in which the use of chemotherapy was very discussed, since docetaxel used to be indicated only in symptomatic patients and in those asymptomatic with poor prognostic criteria.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> The currently available data with the new drugs show that their greatest efficacy is found in asymptomatic or minimally symptomatic patients. Consequently, it seems logical to think that now before a patient with CRPCM0, we must attempt to perform the early diagnosis of metastatic involvement. Thus, those patients would have the opportunity to obtain the maximum benefit from these treatments. Is that so? or are we facing a new scenario where increased survival is only the result of a bias in time, produced by starting a treatment before? The answer to this question is complex and it could only be answered by a prospective and randomized study, specifically designed to answer this question.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Early identification of dissemination in patients with CRPCM0 requires a proactive attitude to detect metastases. The problem lies in the lack of sensitivity of the conventionally used imaging tests (bone scan, computed tomography, conventional MRI) to detect dissemination.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> The study of the control arm of the clinical trial that compared denosumab with placebo in the prevention of bone metastases in patients with high risk of dissemination (CRPCM0 and PSA greater than 8 or PSADT <10 months) has provided valuable information defining a geometric increase in the likelihood of developing bone metastases when the PSA doubling time is shorter than 6 months; however, this study does not provide information about other metastatic sites.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Positron-emission tomography (PET-CT), performed with choline, has been studied mainly in patients with biochemical relapse after radical prostatectomy and its effectiveness is discreet in patients with serum PSA levels lower than 1<span class="elsevierStyleHsp" style=""></span>ng/ml.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> A recent meta-analysis has shown that the sensitivity of choline PET-CT in these patients is associated with the PSA kinetics.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> The only study reported in the literature, which analyzes the effectiveness of choline PET-CT in patients with CRPC, and therefore with serum PSA greater than 2<span class="elsevierStyleHsp" style=""></span>ng/ml shows efficacy greater than 80%, ranging from 63% when the PSA is lower than 5<span class="elsevierStyleHsp" style=""></span>ng/ml and 86% when the PSA is greater.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> In this series of 157 patients, a significant ratio of the positivity of the test with the PSA kinetics was also observed. Another very recent study found a significant relationship between the findings of choline PET-CT and survival of patients with CRPC after radical prostatectomy. The positivity of PET-CT, the serum PSA level, and a sum of Gleason greater than 7 were independent factors in predicting cancer-specific survival.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Whole-body magnetic resonance imaging (WBMRI) with diffusion is another alternative for exploring the presence of metastases in these patients<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a>. To date, only one study has compared the effectiveness of PET-CT and RMCE in diagnosing bone metastases in patients with prostate cancer. This study was conducted in 49 patients with high-risk prostate cancer in the context of their initial staging, and it concludes that PET-CT would be a more sensitive test but somewhat less specific than RMCE.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">We would like to conclude by suggesting first that the use of new forms of effective treatment in patients with asymptomatic CRPCM1 requires a proactive attitude in the early diagnosis of the dissemination. Secondly, that in this scenario the choline PET-CT or RMCE would be the most effective tests to evidence early dissemination. Third, that some studies must be conducted to refine more precisely the performance of these tests based on some clinical parameters, especially serum PSA level and its kinetics, and define the sequence in case of negativity. Finally, we have to point out that this scenario may be relevant in time until effective treatments are approved for CRPCM0 or because the incidence of these patients is reduced due to better use of androgen suppression.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Morote J, Planas J, Maldonado X, Carles J. Cáncer de próstata resistente a castración no diseminado (CPRCM0), un viejo escenario con interés clínico renovado. Actas Urol Esp. 2014;38:419–420.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Heidenreich" 1 => "P.J. Bastian" 2 => "J. Bellmunt" 3 => "M. Bolla" 4 => "S. Joniau" 5 => "T. van der Kwast" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2013.11.002" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2014" "volumen" => "65" "paginaInicial" => "467" "paginaFinal" => "479" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24321502" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Abiraterone in metastatic prostate cancer without previous chemotherapy" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "COU-AA-302 Investigators" "etal" => true "autores" => array:6 [ 0 => "C.J. Ryan" 1 => "M.R. Smith" 2 => "J.S. de Bono" 3 => "A. Molina" 4 => "C.J. Logothetis" 5 => "P. de Souza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1209096" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2013" "volumen" => "368" "paginaInicial" => "138" "paginaFinal" => "148" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23228172" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "TAX 327 Investigators" "etal" => true "autores" => array:6 [ 0 => "I.F. Tannock" 1 => "R. de Wit" 2 => "W.R. Berry" 3 => "J. Horti" 4 => "A. Pluzanska" 5 => "K.N. Chi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa040720" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "351" "paginaInicial" => "1502" "paginaFinal" => "1512" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15470213" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Prostate Cancer Clinical Trials Working Group" "etal" => true "autores" => array:6 [ 0 => "H.I. Scher" 1 => "S. Halabi" 2 => "I. Tannock" 3 => "Morris M." 4 => "Sternberg C.N." 5 => "Carducci M.A." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2007.12.4487" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2008" "volumen" => "26" "paginaInicial" => "1148" "paginaFinal" => "1159" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18309951" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.R. Smith" 1 => "F. Saad" 2 => "S. Oudard" 3 => "N. Shore" 4 => "K. Fizazi" 5 => "P. Sieber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2012.44.6716" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2013" "volumen" => "31" "paginaInicial" => "3800" "paginaFinal" => "3806" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24043751" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. Treglia" 1 => "L. Ceriani" 2 => "R. Sadeghi" 3 => "G. Giovacchini" 4 => "L. Giovanella" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Chem Lab Med" "fecha" => "2013" "volumen" => "5" "paginaInicial" => "1" "paginaFinal" => "9" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Ceci" 1 => "P. Castellucci" 2 => "T. Graziani" 3 => "R. Schiavina" 4 => "E. Brunocilla" 5 => "R. Mazzarotto" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2013" "volumen" => "40" "paginaInicial" => "49" "paginaFinal" => "55" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Giovacchini" 1 => "M. Picchio" 2 => "R. García-Parra" 3 => "A. Briganti" 4 => "F. Abdollah" 5 => "L. Gianolli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2967/jnumed.113.123380" "Revista" => array:6 [ "tituloSerie" => "J Nucl Med" "fecha" => "2014" "volumen" => "55" "paginaInicial" => "233" "paginaFinal" => "241" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24408897" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel imaging techniques reshape the landscape in high-risk prostate cancers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F.E. Lecouvet" 1 => "R. Lhommel" 2 => "V. Pasoglou" 3 => "A. Larbi" 4 => "F. Jamar" 5 => "B. Tombal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MOU.0b013e328361d451" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Urol" "fecha" => "2013" "volumen" => "23" "paginaInicial" => "323" "paginaFinal" => "330" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23619580" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "F. Mosavi" 1 => "S. Johansson" 2 => "D.T. Sandberg" 3 => "I. Turesson" 4 => "J. Sorensen" 5 => "H. Ahlstrom" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Roentgenol" "fecha" => "2012" "volumen" => "199" "paginaInicial" => "1114" "paginaFinal" => "1120" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000003800000007/v1_201408240422/S217357861400122X/v1_201408240422/en/main.assets" "Apartado" => array:4 [ "identificador" => "6293" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000003800000007/v1_201408240422/S217357861400122X/v1_201408240422/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357861400122X?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2023 March | 1 | 0 | 1 |
| 2018 June | 0 | 1 | 1 |
| 2018 February | 22 | 0 | 22 |
| 2018 January | 9 | 1 | 10 |
| 2017 December | 13 | 0 | 13 |
| 2017 November | 22 | 1 | 23 |
| 2017 October | 18 | 1 | 19 |
| 2017 September | 6 | 1 | 7 |
| 2017 August | 10 | 2 | 12 |
| 2017 July | 7 | 2 | 9 |
| 2017 June | 10 | 3 | 13 |
| 2017 May | 6 | 2 | 8 |
| 2017 April | 9 | 2 | 11 |
| 2017 March | 9 | 12 | 21 |
| 2017 February | 17 | 3 | 20 |
| 2017 January | 6 | 0 | 6 |
| 2016 December | 9 | 6 | 15 |
| 2016 November | 19 | 5 | 24 |
| 2016 October | 33 | 13 | 46 |
| 2016 September | 8 | 1 | 9 |
| 2016 August | 1 | 0 | 1 |
| 2016 June | 0 | 1 | 1 |
| 2016 May | 0 | 3 | 3 |
| 2016 February | 0 | 1 | 1 |
| 2015 December | 0 | 2 | 2 |
| 2015 November | 2 | 0 | 2 |
| 2015 August | 0 | 1 | 1 |
| 2015 July | 0 | 1 | 1 |
| 2015 March | 0 | 1 | 1 |
| 2015 February | 0 | 1 | 1 |
| 2015 January | 1 | 0 | 1 |
| 2014 November | 0 | 1 | 1 |
| 2014 October | 0 | 2 | 2 |
| 2014 September | 1 | 1 | 2 |
| 2014 August | 0 | 1 | 1 |
Show all
